Abstract
Takayasu’s arteritis (TA) is a rare granulomatous vasculitic disease that affects the aorta and its major branches. Recent studies have suggested that anti-TNFα biological therapies are highly effective in treating TA refractory to conventional immunosuppressive therapy. We describe two patients with TA: one with progressive TA despite management with two different anti-TNFα agents, infliximab and adalimumab, and another who developed TA while treated with infliximab for the management of pre-existing Crohn’s disease. From our observations, we believe that a multicentered randomized study should be designed to assess the extent of resistance to these agents when different therapeutic doses are employed for managing TA.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baumgart DC, Sandborn WJ (2007) Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369(9573):1641–5167
Reny JL et al (2003) Association of Takayasu’s arteritis and Crohn’s disease: results of a study on 44 Takayasu patients and review of the literature. Ann Med Interne (Paris) 154(2):85–90
Chung SA, Seo P (2009) Advances in the use of biologic agents for the treatment of systemic vasculitis. Curr Opin Rheumatol 21(1):3–9
Maffei S et al (2009) Refractory Takayasu arteritis successfully treated with infliximab. Eur Rev Med Pharmacol Sci 13(1):63–65
Molloy ES et al (2008) Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 67(11):1567–1569
Filocamo G et al (2008) Treatment of Takayasu’s arteritis with tumor necrosis factor antagonists. J Pediatr 153(3):432–434
Wolbink GJ et al (2005) Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 64(5):704–707
St Clair EW et al (2002) The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(6):1451–1459
Wolbink GJ et al (2006) Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 54(3):711–715
Baert F et al (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 348(7):601–608
Bartelds GM et al (2010) Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-TNF naive patients: a cohort study. Ann Rheum Dis 69(5):817–821
El-Matary W, Persad R (2009) Takayasu’s aortitis and infliximab. J Pediatr 155(1):151
Farrant M et al (2008) Takayasu’s arteritis following Crohn’s disease in a young woman: any evidence for a common pathogenesis? World J Gastroenterol 14(25):4087–4090
Levitsky J, Harrison JR, Cohen RD (2002) Crohn’s disease and Takayasu’s arteritis. J Clin Gastroenterol 34(4):454–456
Owyang C et al (1979) Takayasu’s arteritis in Crohn’s disease. Gastroenterology 76(4):825–828
Friedman CJ, Tegtmeyer CJ (1979) Crohn’s disease associated with Takayasu’s arteritis. Dig Dis Sci 24(12):954–958
Johnston SL, Lock RJ, Gompels MM (2002) Takayasu arteritis: a review. J Clin Pathol 55(7):481–486
Karlinger K et al (2000) The epidemiology and the pathogenesis of inflammatory bowel disease. Eur J Radiol 35(3):154–167
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Osman, M., Aaron, S., Noga, M. et al. Takayasu’s arteritis progression on anti-TNF biologics: a case series. Clin Rheumatol 30, 703–706 (2011). https://doi.org/10.1007/s10067-010-1658-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-010-1658-1